
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings is a regenerative medicine company with a focus on the advanced wound care and surgical & sports medicine markets. With a projected revenue increase for the next few years and a diverse product portfolio, the company is well positioned for growth. Though there may be initial dips in revenue due to reimbursement policy changes, the company is expected to recover and their stock is currently undervalued compared to their competitors.
Bears say
Organogenesis Holdings is facing significant challenges in the wound care market due to reimbursement uncertainties caused by CMS decisions in 2026. This has resulted in a decline in stock value and limited potential for upward revisions and multiple expansion. The company has a potential growth opportunity with its ReNu product, but the uncertainty surrounding FDA approval and commercialization makes it difficult to underwrite. Additionally, CMS changes have had a significant impact on the company’s revenue and profitability, with a potential hit to EBITDA for the first time in several years. However, ORGO remains one of the leaders in the regenerative medicine wound care market, with FDA approved products and a potential TAM of over $10 billion. ORGO also faces risks such as potential dilution from future capital raises and failure to secure FDA approval for ReNu. With limited visibility into its business and mixed clinical data, it is currently difficult to accurately forecast the impact of these changes on ORGO’s revenue and profitability.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares